Author & year (No. of patients) | Present study (41) | Sperduto et al. 2010[22] (299) | Videtic et al. 2007[23] (154) | Rades et al. 2013[24] (86) |
---|---|---|---|---|
Initial treatment | ||||
SRS | 100% | 4% | 1% | 0% |
WBRT | 0% | 83% | 84% | 100% |
Patients with 1–3 BM | 68% | 61% | NA | 28% |
Overall MST in months | 8.1 | 4.9 | 4.9 | NA |
DS-GPA (MST in months) | ||||
0-1.0 | 7.2 (20) | 2.8 | ||
1.5-2.5 | 8.1 (15) | 5.3 | ||
3.0 | 24.3 (5) | 9.6 | ||
3.5-4.0 | 10.3 (1) | 17.1 | ||
RTOG-RPA (MST in months) | ||||
Class III | 6.7 (6) | 2.5 | ||
Class II | 8.3 (25) | 5.3 | ||
Class I | 9.2 (10) | 8.6 | ||
Rades’ score (6-months survival rate) | ||||
5-8 | 44% (9) | 3% | ||
9-12 | 73% (22) | 41% | ||
15 | 80% (10) | 89% |